Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 39,800 shares, an increase of 26.3% from the December 31st total of 31,500 shares. Based on an average daily trading volume, of 569,300 shares, the days-to-cover ratio is currently 0.1 days.

Astellas Pharma Stock Down 2.1 %

ALPMY stock traded down $0.21 during trading hours on Friday, reaching $9.68. 94,828 shares of the stock were exchanged, compared to its average volume of 252,637. The firm’s 50-day moving average is $9.87 and its 200-day moving average is $10.97. Astellas Pharma has a 12 month low of $9.05 and a 12 month high of $13.14. The company has a market cap of $17.52 billion, a price-to-earnings ratio of 46.10 and a beta of 0.34. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.10 and a quick ratio of 0.86.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $3.11 billion during the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. On average, equities research analysts expect that Astellas Pharma will post 0.58 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.